Copy to clipboard 
BONESUPPORT reported orthopedic sales of SEK 237.5 million (USD $22.1 million) in 3Q24, up 50.1% from the third quarter of 2023. The company generated SEK 641.7 million (USD $59.7 million) year-to-date, up 53.4% from the prior period.
The company’s continued success with CERAMENT G in the U.S. drove its fourth consecutive quarter with growth over 100%. BONESUPPORT’s total North American sales grew nearly 60% and now comprise 72% of company revenue. CERAMENT G continues gaining hospital approvals, with several major hospitals in California coming on board during the third quarter.
Outside the U.S., BONESUPPORT experienced more impact from seasonality than expect, with healthcare staffing disruptions and surgical volume softness in several regions.
The company received results from the SOLARIO study during the quarter as well, highlighting the benefit of CERAMENT G and CERAMENT V in fight against antibiotic resistance within orthopedics. BONESUPPORT said “patients with orthopedic infections, who are treated surgically with antibiotic-eluting bone replacement materials such as CERAMENT G and CERAMENT V, achieve equally good infection prevention with a short systemic course of antibiotics of a maximum of seven days, compared to current standard treatment that extends over at least four weeks.”
Patients in the shorter treatment group had an average of 47 fewer antibiotic days than the standard treatment group, and reported fewer and milder side effects.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 3Q24 | 3Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| Orthobiologics | $22.1 | $14.7 | $7.4 | 50.1% |
| Segment | 9m24 | 9m23 | $ Chg | % Chg |
|---|---|---|---|---|
| Orthobiologics | $59.7 | $38.9 | $20.8 | 53.4% |
Orthopedic Sales by Geography
| Region | 3Q24 | 3Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| North America | $17.9 | $11.3 | $6.6 | 58.7% |
| EU and ROW | $4.2 | $3.5 | $0.8 | 22.2% |
| Total | $22.1 | $14.7 | $7.4 | 50.1% |
| Region | 9m24 | 9m23 | $ Chg | % Chg |
|---|---|---|---|---|
| North America | $47.1 | $28.9 | $18.2 | 63% |
| EU and ROW | $12.6 | $10.0 | $2.6 | 25.7% |
| Total | $59.7 | $38.9 | $20.8 | 53.4% |
BONESUPPORT reported orthopedic sales of SEK 237.5 million (USD $22.1 million) in 3Q24, up 50.1% from the third quarter of 2023. The company generated SEK 641.7 million (USD $59.7 million) year-to-date, up 53.4% from the prior period.
The company's continued success with CERAMENT G in the U.S. drove its fourth consecutive quarter with...
BONESUPPORT reported orthopedic sales of SEK 237.5 million (USD $22.1 million) in 3Q24, up 50.1% from the third quarter of 2023. The company generated SEK 641.7 million (USD $59.7 million) year-to-date, up 53.4% from the prior period.
The company’s continued success with CERAMENT G in the U.S. drove its fourth consecutive quarter with growth over 100%. BONESUPPORT’s total North American sales grew nearly 60% and now comprise 72% of company revenue. CERAMENT G continues gaining hospital approvals, with several major hospitals in California coming on board during the third quarter.
Outside the U.S., BONESUPPORT experienced more impact from seasonality than expect, with healthcare staffing disruptions and surgical volume softness in several regions.
The company received results from the SOLARIO study during the quarter as well, highlighting the benefit of CERAMENT G and CERAMENT V in fight against antibiotic resistance within orthopedics. BONESUPPORT said “patients with orthopedic infections, who are treated surgically with antibiotic-eluting bone replacement materials such as CERAMENT G and CERAMENT V, achieve equally good infection prevention with a short systemic course of antibiotics of a maximum of seven days, compared to current standard treatment that extends over at least four weeks.”
Patients in the shorter treatment group had an average of 47 fewer antibiotic days than the standard treatment group, and reported fewer and milder side effects.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 3Q24 | 3Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| Orthobiologics | $22.1 | $14.7 | $7.4 | 50.1% |
| Segment | 9m24 | 9m23 | $ Chg | % Chg |
|---|---|---|---|---|
| Orthobiologics | $59.7 | $38.9 | $20.8 | 53.4% |
Orthopedic Sales by Geography
| Region | 3Q24 | 3Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| North America | $17.9 | $11.3 | $6.6 | 58.7% |
| EU and ROW | $4.2 | $3.5 | $0.8 | 22.2% |
| Total | $22.1 | $14.7 | $7.4 | 50.1% |
| Region | 9m24 | 9m23 | $ Chg | % Chg |
|---|---|---|---|---|
| North America | $47.1 | $28.9 | $18.2 | 63% |
| EU and ROW | $12.6 | $10.0 | $2.6 | 25.7% |
| Total | $59.7 | $38.9 | $20.8 | 53.4% |
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
